Flipper44,
You wrote:
“Remember, one of the reasons I don't think there is likely much crossover impact in the current phase III trial (barring midstream manufacturing modification) is that the vaccine for crossovers will be based on the original tumor, not the recurrent and/or progressing tumor.)” (post 173725)
and you wrote:
-“Yes, hence why I see less chance for big crossover impact in the phase III trial (unless there was midstream optimization)”
-“(If there was a more potent version of DCVax-L created midstream, the more potent version might be able to help original placebos more. les is saying, apparently, off the record there was no midstream optimization in manufacturing.)” (post 173776)
But at the ASM ( 27 April 2018) Les Goldman give us the impression that everybody who is getting the vaccine is living longer! (See Notes 6 Beartrap12)
Quote:
“Les: I think its important for everyone following us, to take a step back and look and say, it can't be a bad thing if everybody getting the vaccine is living longer. So it becomes a question that with all the new policy initiatives at the FDA and overseas, how do our facts fit into this and as Linda says, it's still a work in progress to find the exact right slots, but the bottom line is if we have something where everyone who's had the vaccine is living longer, that's a pretty good thing. We shouldn't lose sight of this in the context of all the rules that used to be, and might be and are gonna be. People on the otherside of this would like to use that to camoflauge the reality of what may be unfolding.
Linda interjects “it's a maybe and we don't actually know for sure.”
Les: We don't know for sure.”
Flipper44, can you explain your point?
Thanks.
